AMENDMENTS

Please enter the following amendments without prejudice or disclaimer.

In the claims:

Please cancel claims 33-40, 47, 51-53, 58 and 59, without prejudice or disclaimer.

Please amend claims 41-46, 48-50, 54-57 and 60-64 as follows.

---

41. (Twice Amended) The method of claim 65 wherein said RPE cells or cells of said population of non-RPE cells are attached to a matrix prior to administration.

42. (Twice Amended) The method of claim 65 wherein said RPE cells and cells of said population of non-RPE cells are attached to a matrix prior to administration.

43. (Amended) The method of claim 65 wherein said administering is by transplantation.

44. (Amended) The method of claim 65 wherein said RPE cells are administered in a dose ranging from 10^3 to 10^7 cells.

45. (Twice Amended) The method of claim 65 wherein said non-RPE cell population is administered in a dose ranging from 10^3 to 10^7 cells.

46. (Amended) The method of claim 65, further comprising re-administering RPE cells to the site in an effective amount to sustain survival of the allogeneic non-RPE cells.

---

48. (Twice Amended) The method of claim 46 wherein the RPE cells for re-administration are attached to a matrix prior to re-administration.

49. (Twice Amended) The method according to claim 65 wherein the RPE cells and the population of non-RPE cells are administered as a single composition.

50. (Twice Amended) The method according to claim 65 wherein the RPE cells and the population of non-RPE cells are administered as separate compositions.

54. (Twice Amended) A pharmaceutical composition comprising retinal pigment epithelial (RPE) cells, a non-RPE cell population, and a pharmaceutically acceptable carrier,

wherein said non-RPE cell population is allogeneic to said RPE cells and wherein the ratio of RPE cells to non-RPE cells is sufficient to be useful in the method of claim 65.

55. (Amended) The composition of claim 54 wherein said population of non-RPE cells produces a biologically active molecule that is absent or defective in a disease.

56. (Amended) The composition of claim 54 wherein said non-RPE cell population comprises insulin-producing cells.

57. (Amended) The composition of claim 56 wherein said insulin-producing cells are pancreatic islet of Langerhans cells.

60. (Twice Amended) A pharmaceutical composition comprising retinal pigment epithelial (RPE) cells and a non-RPE cell population, wherein said non-RPE cell population is allogeneic to said RPE cells, wherein the ratio of RPE cells to non-RPE cells is sufficient to be

useful in the method of claim 65 and wherein said RPE cells and cells of the population of non-RPE cells are attached to a matrix.

61. (Twice Amended) A compartmentalized kit adapted to receive a first container adapted to contain retinal pigment epithelial (RPE) cells and a second container adapted to contain a non-RPE cell population, wherein said RPE cells are allogeneic to said non-RPE cell population and wherein the ratio of RPE cells to non-RPE cells provided in the kit is sufficient to be useful in the method of claim 65.

62. (Twice Amended) The compartmentalized kit according to claim 61, wherein the non-RPE cell population comprises insulin-producing cells.

63. (Amended) The compartmentalized kit according to claim 62, wherein the insulin-producing cells are pancreatic islet of Langerhans cells.

64. (Twice Amended) An article of manufacture, comprising:

a packaging material;

retinal pigment epithelial (RPE) cells contained within said packaging material;

a non-RPE cell population contained within said packaging material, wherein said non-RPE cell population is allogeneic to said RPE cells;

wherein the ratio of RPE cells to non-RPE cells contained within said packaging material is sufficient to be useful in the method of claim 65; and

wherein said packaging material contains a label that indicates that said RPE cells can be used for facilitating survival of an allogeneic graft in a mammal.

Please add new claims 65-73 as follows.

65. (New) A method for facilitating survival of an allogeneic graft, comprising: administering retinal pigment epithelial (RPE) cells and a population of non-RPE cells to a site in a mammal, wherein the population of non-RPE cells is allogeneic to the mammal, thereby increasing survival time of the population of non-RPE cells.

66. (New) The method of claim 65 wherein said RPE cells are allogeneic to the mammal.

67. (New) The method of claim 65 wherein said RPE cells are allogeneic to said population of non-RPE cells.

68. (New) The method of claim 41 wherein said RPE cells are attached to a matrix prior to administration.

69. (New) The method of claim 41 wherein said cells of said population of non-RPE cells are attached to a matrix prior to administration.

70. (New) The composition of claim 54 wherein said RPE cells are attached to a matrix.

71. (New) The composition of claim 54 wherein cells of said population of non-RPE cells are attached to a matrix.

72. (New) The article of manufacture according to claim 64, wherein the non-RPE cell population comprises insulin-producing cells.

73. (New) The article of manufacture according to claim 72, wherein the insulin-producing cells are pancreatic islet of Langerhans cells.